{
    "clinical_study": {
        "@rank": "16669", 
        "arm_group": {
            "arm_group_label": "Multiple Myeloma Patients Treated with Revlimid (lenalidomide)", 
            "description": "Single Cohort of Multiple Myeloma Patients Treated with Revlimid"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to document efficacy and safety data in a real-world\n      setting of Chinese multiple myeloma patients who have received at least one prior therapy\n      treated with REVLIMID (lenalidomide)."
        }, 
        "brief_title": "Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This registry is prospective, multi-center, observational study and will collect efficacy\n      and safety data on multiple myeloma adult patients who have received at least one prior\n      therapy and take REVLIMID as part of standard care associated with patients' treatment in\n      order to characterize the use, efficacy and outcomes of REVLIMID treatment.\n\n      The registry will capture data from 600 patients being prescribed REVLIMID in specified\n      hospitals and all patients will be followed in the registry for two years after enrollment\n      of the last patient."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must understand and voluntarily sign written informed consent At least 18 years old\n             at the time of signing informed consent Diagnosed with Multiple Myeloma Must have\n             received at least one prior Multiple Myeloma treatment at the time of signing\n             informed consent\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult Chinese Patients with Multiple Myeloma Treated with Revlimid (Lenalidomide) in a\n        Postmarketing setting"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947309", 
            "org_study_id": "NIPMS-RV-CN-001"
        }, 
        "intervention": {
            "arm_group_label": "Multiple Myeloma Patients Treated with Revlimid (lenalidomide)", 
            "description": "Revlimid (lenalidomide) as prescribed in usual clinical practice", 
            "intervention_name": "Revlimid (lenalidomide)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lenalidomide", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Revlimid, lenalidomide, multiple myeloma, PFS, Response Rates", 
        "lastchanged_date": "September 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100044"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100020"
                    }, 
                    "name": "Peking Chao-Yang Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100730"
                    }, 
                    "name": "Beijing Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100071"
                    }, 
                    "name": "People's Liberation Army Hospital 307"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "zip": "130031"
                    }, 
                    "name": "The Fisrt Hospital Of Jilin University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "zip": "410008"
                    }, 
                    "name": "Xiangya Hospital Central-South University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "410008"
                    }, 
                    "name": "Xinqiao Hospital, 3rd Military Medical University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510515"
                    }, 
                    "name": "NanFang Hospital of China Southern Medical University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "zip": "230032"
                    }, 
                    "name": "The First Affliated Hospital of Anhui Medical University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "zip": "250012"
                    }, 
                    "name": "Qilu Hospital of Shandong University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China", 
                        "zip": "266003"
                    }, 
                    "name": "The Affiliated Hospital of Mecical College Qingdao University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200003"
                    }, 
                    "name": "Shanghai Changzhen Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "zip": "110004"
                    }, 
                    "name": "The Second Affiliated Hospital Of China Medical University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "zip": "215006"
                    }, 
                    "name": "The First Affiliated Hospital of Suzhou University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urumqi", 
                        "country": "China", 
                        "zip": "830001"
                    }, 
                    "name": "People's Hospital of Xinjiang Uygur Autonomous Region"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "zip": "430000"
                    }, 
                    "name": "Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science & Technology"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "zip": "430030"
                    }, 
                    "name": "Tongji Medical College Huazhong University of Science & Technology"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China", 
        "overall_contact": {
            "last_name": "Associate Director, Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Pharmaceutical (Shanghai) Co. Ltd.", 
            "last_name": "Yu (Flora) Yao, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessment of PFS using IMWG Uniform Response Criteria", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years after enrollment of last patient"
            }, 
            {
                "description": "Assessment of Response Rates (CR, VGPR, PR) using IMWG Uniform Response Criteria", 
                "measure": "Response Rates", 
                "safety_issue": "No", 
                "time_frame": "2 years after enrollment of last patient"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival  (OS)", 
                "safety_issue": "No", 
                "time_frame": "Two years after last patient enrolled"
            }, 
            {
                "measure": "Time to Response (TTR) and Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Two years after last patient enrolled"
            }, 
            {
                "description": "Reason for dose interruption/reduction of REVLIMID, if this occurs.  Reason for discontinuation of REVLMID", 
                "measure": "Duration of Treatment with Revlimid", 
                "safety_issue": "Yes", 
                "time_frame": "Two years after last patient enrolled."
            }, 
            {
                "description": "All Adverse Events (AEs) and occurrence of second primary malignancies (SPM)", 
                "measure": "Safety Profile of Revlimid", 
                "safety_issue": "Yes", 
                "time_frame": "Two years after last patient enrolled"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}